Skip to main content

Advertisement

Table 1 Study data used for the evidence synthesis

From: Application of Bayesian evidence synthesis to modelling the effect of ketogenic therapy on survival of high grade glioma patients

Year First author Species Tumor Treatment NT + NC RMSTT RMSTC MR Data source
2014 Han Humans GBM CR+ 11 + 23 41.36 ± 4.02 23.70 ± 2.85 1.75 ± 0.27 Figure
2015 Rieger Humans GBM KD 8 + 5 7.25 ± 1.07 5.16 ± 1.29 1.41 ± 0.41 Figure
2018 Santos Humans GBM KD+ 17 + 15 10.56 ± 0.94 8.38 ± 1.49 1.26 ± 0.25 Author
2007 Zhou C57BL/6J mice CT-2A astrocytoma (syn.) KD 9 + 7 19.78 ± 0.84 17.71 ± 0.94 1.12 ± 0.08 Author
2007 Zhou C57BL/6J mice CT-2A astrocytoma (syn.) CR 11 + 7 31.82 ± 2.26 17.71 ± 0.94 1.80 ± 0.16 Author
2007 Zhou BALBc/J SCID mice U87 glioma (xen.) KD 7 + 11 19.71 ± 0.78 21.27 ± 1.84 0.93 ± 0.09 Author
2007 Zhou BALBc/J SCID mice U87 glioma (xen.) CR 14 + 11 30.36 ± 1.40 21.27 ± 1.84 1.43 ± 0.14 Author
2008 Marsh C57BL/6J mice CT-2A astrocytoma (syn.) CR 8 + 7 30.50 ± 4.09 18.86 ± 1.20 1.62 ± 0.24 Figure
2010 Stafford C57BL/6J albino mice GL261 glioma (syn.) KD 5 + 5 24.00 ± 0.94 19.00 ± 0.63 1.26 ± 0.06 Author
2011 Maurer Athymic mice LNT-229 glioma (xen.) KD 12 + 12 87.83 ± 4.59 96.90 ± 3.57 0.91 ± 0.06 Author
2012 Abdelwahab C57BL/6J albino mice GL261 glioma (syn.) KD 20 + 19 33.90 ± 5.12 23.32 ± 1.08 1.45 ± 0.23 Author
2012 Abdelwahab C57BL/6J albino mice GL261 glioma (syn.) KD+ 11 + 11 97.36 ± 4.93 54.73 ± 9.81 1.78 ± 0.33 Figure
2013 Jiang Athymic mice U87 glioma (xen.) CR 7 + 7 26.71 ± 1.55 18.71 ± 0.85 1.43 ± 0.11 Figure
2014 Rieger Athymic mice U87 glioma (xen.) KD 8 + 8 35.62 ± 0.64 33.88 ± 1.53 1.05 ± 0.05 Author
2014 Rieger Athymic mice U87 glioma (xen.) KD+ 8 + 8 57.50 ± 2.28 50.25 ± 2.24 1.14 ± 0.07 Figure
2015 Martuscello NOD/SCID mice L0 glioma (xen.) KD 10 + 11 48.50 ± 5.63 14.55 ± 1.57 3.33 ± 0.53 Figure
2015 Martuscello NOD/SCID mice L2 glioma (xen.) KD 5 + 6 55.20 ± 8.15 25.5 ± 2.38 2.17 ± 0.38 Figure
2016 De Feyter Fisher rats 9 L glioma (xen.) KD 10 + 9 34.70 ± 1.63 33.56 ± 1.33 1.07 ± 0.07 Author
2016 De Feyter Fisher rats RG2 glioma (xen.) KD 10 + 11 26.30 ± 1.11 27.36 ± 0.71 0.96 ± 0.05 Author
2016 Lussier C57BL/6J albino mice GL261 glioma (syn.) KD 12 + 11 42.17 ± 2.52 33.09 ± 1.45 1.27 ± 0.09 Figure
  1. Subscript “T” denotes treatment group, “C” control group. CR/KD Calorie restriction/ Ketogenic diet as monotherapy, CR+/KD+ Calorie restriction/ ketogenic diet combined with another therapy, syn. syngeneic transplant, xen. xenogeneic transplant